XML 46 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Licensing Agreements (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Jul. 31, 2013
USD ($)
item
May. 31, 2013
USD ($)
item
Mar. 31, 2013
USD ($)
item
Jan. 31, 2013
USD ($)
item
Feb. 28, 2009
USD ($)
item
Sep. 30, 2015
USD ($)
item
Sep. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Sep. 30, 2015
USD ($)
item
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
employee
Dec. 31, 2010
USD ($)
Collaboration research and licensing agreements                          
Revenue recognized             $ 3,503,000 $ 848,000   $ 6,008,000 $ 3,856,000    
Current portion of deferred revenue $ 47,652,000           47,652,000     47,652,000   $ 2,254,000  
Collaboration and Option Agreement | Amgen, Inc.                          
Collaboration research and licensing agreements                          
Option term after delivery of the data from a Phase 2 proof-of-concept (POC) clinical trial                         90 days
Nonrefundable upfront payment                         $ 11,000,000
Milestone payment received         $ 2,000,000                
Revenue recognized               600,000   0 1,700,000    
Deferred revenue 0           0     0      
Option fee                         $ 50,000,000
License Agreement | Merck Sharp & Dohme Corp.                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment   $ 1,000,000                      
Annual maintenance fees   $ 500,000                      
Milestone payment received                 $ 500,000        
Revenue recognized             25,000 25,000   75,000 500,000    
Deferred revenue 75,000           75,000     75,000      
Number of compounds | item   1                      
Portion of nonrefundable upfront payment allocated to option   $ 0                      
License Agreement | Alexion Pharmaceuticals, Inc.                          
Collaboration research and licensing agreements                          
Revenue recognized                   2,500,000      
Option and license agreement | Alexion Pharmaceuticals, Inc.                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment         3,000,000                
Annual maintenance fees         $ 500,000                
Revenue recognized             300,000 200,000   1,300,000 800,000    
Deferred revenue 1,300,000           1,300,000     1,300,000      
Number of different target programs | item         6                
Research license term         5 years                
Additional research term         3 years                
Extension fee         $ 2,000,000                
Annual maintenance fees payable during any extension of research term         1,000,000                
Option fee         $ 4,000,000                
Research term of revenue recognized         5 years                
2009 Research License and Commercialization Agreement | CSL Limited                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment           $ 750,000              
Research license term           5 years              
2009 Research License and Commercialization Agreement | CSL Limited | Maximum                          
Collaboration research and licensing agreements                          
Number of commercial options | item           5              
May 2013 Research License and Commercialization Agreement | CSL Limited                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment     $ 2,500,000                    
Milestone payment received                   2,500,000      
Revenue recognized               0     700,000    
Deferred revenue 0           0     0      
Number of commercial options | item     4                    
March 2013 License Agreement | CSL Limited                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment       $ 500,000                  
Revenue recognized             0 $ 0   0 $ 0    
Deferred revenue 0           0     0      
Number of compounds | item       1                  
Collaboration And License Agreement | Novo Nordisk                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment                       2,500,000  
Potential milestone payment                       $ 2,000,000  
Revenue recognized             700,000     2,100,000      
Deferred revenue 1,900,000           1,900,000     $ 1,900,000      
Research license term                       2 years  
Additional research term                       12 months  
Research funding                       $ 1,600,000  
Number of full time employees that will be given research support | employee                       4  
Research term of revenue recognized                   2 years      
Research and License Agreement 2015 | Amgen, Inc.                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment 45,000,000                        
Potential milestone payment 1,700,000,000                        
Revenue recognized             0     $ 0      
Deferred revenue $ 45,000,000           $ 45,000,000     $ 45,000,000      
Number of different target programs | item 6                        
Number of previously indentified products | item 3           3     3      
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment                   $ 13,750,000      
Potential milestone payment                   355,000,000      
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                          
Collaboration research and licensing agreements                          
Nonrefundable upfront payment                   6,250,000      
Potential milestone payment                   $ 260,500,000      
Research license term                   3 years      
Additional research term                   1 year      
Previous targets which bispecific technology will be applied | item 5           5     5      
Development-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                          
Collaboration research and licensing agreements                          
Potential milestone payment                   $ 55,000,000      
Development-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                          
Collaboration research and licensing agreements                          
Potential milestone payment                   35,500,000      
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                          
Collaboration research and licensing agreements                          
Potential milestone payment                   70,000,000      
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                          
Collaboration research and licensing agreements                          
Potential milestone payment                   55,000,000      
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program                          
Collaboration research and licensing agreements                          
Potential milestone payment                   230,000,000      
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program                          
Collaboration research and licensing agreements                          
Potential milestone payment                   $ 170,000,000